Potential as a Clinical Cancer Therapeutic Agent
  • Janet H. Ransom
  • Linda S. Cleveland
Part of the Contemporary Biomedicine book series (CB, volume 8)


Leukoregulin has not been introduced into clinical trials yet; it has, however, been evaluated in a three-phase preclinical screen. This screen consisted of evaluation of leukoregulin’s growth inhibition of human tumor and normal cell lines, measurement of the inhibition of tumor stem cell colony formation in agar using freshly dissociated human tumor cells, and inhibition of human tumor xenograft growth in athymic nude mice. The data regarding the growth inhibition of human tumor cell lines were presented in the preceeding chapter on leukoregulin. Leukoregulin activity ranging from 1 to 1200 units inhibited human gastrointestinal, bladder, head, and neck carcinomas, glioblastomas, and leukemia cell lines, but not normal cell counterparts. The second phase of the screen, clonogenic growth of tumor cells in semisolid agar medium, has been used as an indicator of patient clinical response with a relatively high degree of correlation (1,2). This type of assay allows for the determination of the types of tumor cells that may respond clinically to a given therapeutic agent. The third phase of the screen, evaluation of growth inhibition of human tumor xenografts, further enables appropriate selection of dosage, route of administration, and length of exposure required for a clinical response.


Human Tumor Cell Human Tumor Cell Line Athymic Nude Mouse Human Tumor Xenograft Lung Tumor Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Van Hoff, D. D., Clark, G. M., Stogdill, B. J., Sarosdy, M. F., O’Brien, M. T., Casper, J. T., Mattox, D. E., Page, C. P., Cruz, A. B., and Sand-bach, J. F. Cancer Res. 43, 1926–1931 (1983).PubMedGoogle Scholar
  2. 2.
    Alonso, K. Cancer 54, 2475–2479 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    Peters, L. C., Brandhorst, J. S., and Hanna, M. G., Jr. Cancer Res. 39, 1353–1360 (1979).PubMedGoogle Scholar
  4. 4.
    Hamburger, A. W. and Salmon, S. E. Science 197, 461–463 (1977).PubMedCrossRefGoogle Scholar
  5. 5.
    Kozlowski, J. M., Fidler, I. J., Campbell, D., Xu Z-l, Kaign, M. E., and Hart, I. R. Cancer Res. 44, 3522–3529 (1984).PubMedGoogle Scholar

Copyright information

© The Humana Press Inc. 1988

Authors and Affiliations

  • Janet H. Ransom
  • Linda S. Cleveland

There are no affiliations available

Personalised recommendations